Featured Intelligence

A new weight-loss pill approved this year works through the same GLP-1 pathway as the injectable drugs that have reshaped obesity treatment, but it is built entirely differently at the molecular level, and that difference matters more than

CAR-T cell therapy was built to fight blood cancers, engineering a patient's own immune cells to hunt down and destroy cancerous B cells. This year, that same basic technology is producing real, closely watched results in a

Several competing companies have now implanted brain-computer interfaces in dozens of paralyzed patients who can genuinely control a computer cursor, type, and communicate using only their thoughts. Synchron's device has been placed in more than fifty patients

A gene therapy for a specific inherited form of deafness has crossed into real, approved medicine, and the results are genuinely striking. In clinical trials, roughly four out of five children treated for OTOF-related hearing loss, a condition caused

NAD+ boosting supplements have been sold on the promise of slowing cellular aging for years, built largely on animal research and plausible biochemistry rather than rigorous human evidence. That changed somewhat this year with a randomized controlled trial that, for

Roughly one in five people carry high levels of lipoprotein(a), a genetically determined particle in the blood linked to heart attack and stroke risk that, unlike standard cholesterol, cannot be meaningfully lowered through diet, exercise, or existing statin drugs.

Age-related muscle loss, the gradual decline in strength and lean mass that makes falls, frailty, and lost independence more likely later in life, has no approved drug treatment anywhere in the world. Bimagrumab, one of the most closely watched

Gut bacteria therapy has quietly become one of the few areas of microbiome science with real, FDA-approved treatments already in use, not just promising early research. Two prescription therapies are now approved specifically to prevent recurrent C. difficile infection,

For several years, pig-to-human organ transplants existed only as isolated, emergency-authorized cases, each one a single data point rather than part of an organized study. That changed when the first formal, multicenter clinical trial of a gene-